Arul Chinnaiyan
#54,939
Most Influential Person Now
Indian scientist, medical researcher
Arul Chinnaiyan's AcademicInfluence.com Rankings
Arul Chinnaiyanlaw Degrees
Law
#1192
World Rank
#1522
Historical Rank
Common Law
#16
World Rank
#18
Historical Rank
International Law
#106
World Rank
#157
Historical Rank
Arul Chinnaiyanbiology Degrees
Biology
#2560
World Rank
#4038
Historical Rank
Computational Biology
#30
World Rank
#30
Historical Rank
Pathology
#20
World Rank
#55
Historical Rank
Download Badge
Law Biology
Why Is Arul Chinnaiyan Influential?
(Suggest an Edit or Addition)According to Wikipedia, Arul M. Chinnaiyan is a Hicks Endowed Professor of Pathology and professor of pathology and urology at the University of Michigan Medical School. He is also a Howard Hughes medical Investigator at the Howard Hughes Medical Institute.
Arul Chinnaiyan's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- ONCOMINE: a cancer microarray database and integrated data-mining platform. (2004) (3315)
- FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex (1996) (3233)
- Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. (2006) (2694)
- FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis (1995) (2607)
- The polycomb group protein EZH2 is involved in progression of prostate cancer (2002) (2596)
- Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. (2007) (2522)
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
- The landscape of long noncoding RNAs in the human transcriptome (2015) (2174)
- The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer (2012) (2144)
- Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. (2007) (2010)
- Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression (2009) (1988)
- TEAD mediates YAP-dependent gene induction and growth control. (2008) (1969)
- The Receptor for the Cytotoxic Ligand TRAIL (1997) (1845)
- Delineation of prognostic biomarkers in prostate cancer (2001) (1733)
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. (2015) (1670)
- The emergence of lncRNAs in cancer biology. (2011) (1665)
- EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells (2003) (1605)
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer (2005) (1539)
- Development of human protein reference database as an initial platform for approaching systems biology in humans. (2003) (1122)
- Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer (2008) (1066)
- CD8+ T cells regulate tumor ferroptosis during cancer immunotherapy (2019) (1049)
- Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. (2004) (1011)
- Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression (2011) (956)
- The Landscape of Circular RNA in Cancer (2019) (920)
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer (2013) (915)
- Transcriptome Sequencing to Detect Gene Fusions in Cancer (2009) (913)
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer (2009) (891)
- Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer (2007) (854)
- FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis (*) (1996) (804)
- An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. (2010) (800)
- Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. (2005) (784)
- Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer (2014) (765)
- Integrative molecular concept modeling of prostate cancer progression (2007) (725)
- Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. (2011) (706)
- Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95 (1996) (701)
- Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. (2002) (693)
- The Role of Non-coding RNAs in Oncology (2019) (684)
- Role of the TMPRSS2-ERG gene fusion in prostate cancer. (2008) (679)
- The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. (2010) (667)
- Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death (1997) (667)
- Genomic correlates of clinical outcome in advanced prostate cancer (2019) (647)
- A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. (2007) (646)
- Molecular Ordering of the Cell Death Pathway (1996) (632)
- Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases (2004) (627)
- Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing (2013) (617)
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study (2011) (612)
- Autoantibody signatures in prostate cancer. (2005) (606)
- The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex (2013) (606)
- Identification of targetable FGFR gene fusions in diverse cancers. (2013) (606)
- alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. (2002) (597)
- Integrative Clinical Genomics of Metastatic Cancer (2017) (574)
- Recurrent gene fusions in prostate cancer (2008) (572)
- Repression of E-cadherin by the polycomb group protein EZH2 in cancer (2008) (566)
- Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. (2000) (547)
- TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. (2006) (539)
- The long tail of oncogenic drivers in prostate cancer (2018) (529)
- TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort (2007) (506)
- Integrative analysis of the cancer transcriptome (2005) (493)
- The CED-3/ICE-like Protease Mch2 Is Activated during Apoptosis and Cleaves the Death Substrate Lamin A* (1996) (493)
- TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. (2006) (488)
- New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. (2009) (485)
- Expression of CXCR4 and CXCL12 (SDF‐1) in human prostate cancers (PCa) in vivo (2003) (473)
- Probabilistic model of the human protein-protein interaction network (2005) (459)
- Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma (2010) (442)
- TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion (2006) (437)
- Beyond PSA: The Next Generation of Prostate Cancer Biomarkers (2012) (417)
- Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. (2011) (398)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (398)
- Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer (2009) (395)
- Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). (2005) (389)
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
- ETS gene fusions in prostate cancer: from discovery to daily clinical practice. (2009) (383)
- A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. (2007) (381)
- Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. (2019) (375)
- The cell-death machine (1996) (374)
- Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA (2011) (364)
- Chimeric transcript discovery by paired-end transcriptome sequencing (2009) (363)
- The bright side of dark matter: lncRNAs in cancer. (2016) (361)
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer (2018) (360)
- Antibody-based detection of ERG rearrangement-positive prostate cancer. (2010) (358)
- JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence (2004) (353)
- A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. (2007) (346)
- Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. (2001) (336)
- ICE-LAP3, a Novel Mammalian Homologue of the Caenorhabditis elegans Cell Death Protein Ced-3 Is Activated during Fas- and Tumor Necrosis Factor-induced Apoptosis (*) (1996) (336)
- Functionally Recurrent Rearrangements of the MAST Kinase and Notch Gene Families in Breast Cancer (2011) (330)
- The role of SPINK1 in ETS rearrangement-negative prostate cancers. (2008) (327)
- Ultraviolet Radiation-induced Apoptosis Is Mediated by Activation of CD-95 (Fas/APO-1)* (1997) (323)
- A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. (2008) (323)
- ICE-LAP6, a Novel Member of the ICE/Ced-3 Gene Family, Is Activated by the Cytotoxic T Cell Protease Granzyme B* (1996) (323)
- Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. (2008) (322)
- Dual roles of PARP-1 promote cancer growth and progression. (2012) (321)
- Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer (2007) (319)
- Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. (2016) (318)
- Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. (2005) (311)
- Common gene rearrangements in prostate cancer. (2011) (305)
- Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. (2015) (304)
- Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction (2015) (298)
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. (2017) (295)
- Alpha-Methylacyl-CoA Racemase: A Novel Tumor Marker Over-expressed in Several Human Cancers and Their Precursor Lesions (2002) (293)
- Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. (2008) (283)
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma (2019) (283)
- ChimeraScan: a tool for identifying chimeric transcription in sequencing data (2011) (276)
- Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. (2003) (275)
- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination (2021) (268)
- A role for FADD in T cell activation and development. (1998) (267)
- Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. (2006) (259)
- Expressed Pseudogenes in the Transcriptional Landscape of Human Cancers (2012) (258)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (2015) (256)
- PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. (2014) (249)
- EML4-ALK fusion lung cancer: a rare acquired event. (2008) (248)
- The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. (2015) (248)
- PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. (2012) (244)
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. (2018) (239)
- RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. (2014) (236)
- The apoptosome: heart and soul of the cell death machine. (1999) (233)
- The Potential of MicroRNAs as Prostate Cancer Biomarkers. (2016) (232)
- Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. (2007) (229)
- Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States (2009) (229)
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression (2018) (227)
- Long noncoding RNAs in cancer: from function to translation. (2015) (225)
- Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression (2009) (224)
- Mixture modelling of gene expression data from microarray experiments (2002) (221)
- A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. (2005) (220)
- Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. (2007) (220)
- Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. (2011) (218)
- Coordinated regulation of polycomb group complexes through microRNAs in cancer. (2011) (217)
- Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. (2009) (215)
- Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo (2006) (215)
- Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. (2013) (211)
- Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. (2003) (203)
- Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors (2006) (202)
- Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer (2006) (199)
- Role of CED-4 in the activation of CED-3 (1997) (199)
- Proteogenomic Characterization of Endometrial Carcinoma (2020) (194)
- Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy (2017) (193)
- The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression (2016) (190)
- Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. (2001) (189)
- Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin (2015) (189)
- Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition (2007) (189)
- FIZZ1 stimulation of myofibroblast differentiation. (2004) (187)
- Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. (2011) (185)
- Mining for regulatory programs in the cancer transcriptome (2005) (180)
- C5a-induced gene expression in human umbilical vein endothelial cells. (2004) (179)
- Cancer SLC43A2 alters T cell methionine metabolism and histone methylation (2020) (179)
- Dysregulation of the annexin family protein family is associated with prostate cancer progression. (2003) (179)
- Cancer transcriptome profiling at the juncture of clinical translation (2017) (176)
- Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA (2017) (176)
- Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. (2011) (175)
- Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. (2008) (173)
- From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer (2012) (173)
- The Role of Calpain in the Proteolytic Cleavage of E-cadherin in Prostate and Mammary Epithelial Cells* (2003) (172)
- Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia (2013) (166)
- Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. (2016) (163)
- A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. (2008) (159)
- Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer (2004) (159)
- Targeting the MLL complex in castration resistant prostate cancer (2015) (158)
- Metabolism unhinged: IDH mutations in cancer (2011) (157)
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. (2017) (155)
- Calcitic microlenses as part of the photoreceptor system in brittlestars (154)
- SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. (2017) (153)
- ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients (2015) (152)
- Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. (2002) (151)
- Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression (2018) (151)
- The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy (2007) (151)
- The role of sarcosine metabolism in prostate cancer progression. (2013) (150)
- Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. (2004) (150)
- Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. (2007) (148)
- The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc12 (2014) (146)
- Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer (2019) (146)
- Therapeutic Targeting of SPINK1-Positive Prostate Cancer (2011) (146)
- alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. (2002) (145)
- AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist (2009) (144)
- CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases. (1996) (144)
- Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. (2016) (143)
- Integrative analysis of genomic aberrations associated with prostate cancer progression. (2007) (139)
- The landscape of antisense gene expression in human cancers (2015) (139)
- Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. (2011) (139)
- Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. (2013) (136)
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer (2018) (135)
- Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. (2007) (134)
- Delineation, Functional Validation, and Bioinformatic Evaluation of Gene Expression in Thyroid Follicular Carcinomas with the PAX8-PPARG Translocation (2006) (134)
- Quantitative Proteomic Profiling of Prostate Cancer Reveals a Role for miR-128 in Prostate Cancer* (2009) (134)
- A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors (2018) (133)
- Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2 (2020) (133)
- The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing (2015) (133)
- Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. (2006) (132)
- Translating cancer genomes and transcriptomes for precision oncology (2016) (132)
- Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. (2006) (132)
- Melanoma proliferation and chemoresistance controlled by the DEK oncogene. (2009) (132)
- The Central Role of EED in the Orchestration of Polycomb Group Complexes (2014) (131)
- Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data (2004) (131)
- Decreased α-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death (2005) (131)
- The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression (2004) (129)
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer (2016) (129)
- The lncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer (2014) (129)
- HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data (2010) (127)
- TACO produces robust multi-sample transcriptome assemblies from RNA-seq (2016) (126)
- Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. (2012) (126)
- Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors12 (2015) (126)
- Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas (2016) (126)
- CXCL5 promotes prostate cancer progression. (2008) (125)
- Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases (2009) (125)
- Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors (2006) (125)
- Classification and Selection of Biomarkers in Genomic Data Using LASSO (2005) (124)
- Humoral Immune Response to α-Methylacyl-CoA Racemase and Prostate Cancer (2004) (122)
- Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells (2006) (121)
- Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma (2012) (121)
- Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors (2004) (121)
- CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER (2008) (120)
- Transcriptome Meta-Analysis of Lung Cancer Reveals Recurrent Aberrations in NRG1 and Hippo Pathway Genes (2014) (120)
- Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. (2016) (119)
- Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. (2021) (118)
- Landscape of gene fusions in epithelial cancers: seq and ye shall find (2015) (114)
- The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of D (2014) (113)
- Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. (2009) (113)
- On the detection and refinement of transcription factor binding sites using ChIP-Seq data (2010) (111)
- KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. (2008) (111)
- Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. (2006) (110)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (110)
- ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. (2006) (110)
- Molecular Cross-talk between the TRAIL and Interferon Signaling Pathways* 210 (2002) (110)
- Defining aggressive prostate cancer using a 12-gene model. (2006) (110)
- Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer (2020) (109)
- Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. (1997) (107)
- Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. (2018) (106)
- Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty (2005) (106)
- Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences (2010) (105)
- The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. (2005) (104)
- Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3 (1996) (103)
- Characterization of KRAS rearrangements in metastatic prostate cancer. (2011) (102)
- Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. (2011) (101)
- Statistical issues and methods for meta-analysis of microarray data: a case study in prostate cancer (2003) (101)
- Proteogenomic characterization of pancreatic ductal adenocarcinoma (2021) (101)
- Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. (2016) (100)
- DNA methylation landscapes in advanced prostate cancer (2020) (98)
- TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer (2014) (98)
- Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23–qter and identifies underlying candidate tumor suppressor genes in prostate cancer (2004) (98)
- A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. (2002) (97)
- Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast (2014) (96)
- Advancing precision medicine for prostate cancer through genomics. (2013) (96)
- Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. (2005) (95)
- Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. (2008) (95)
- Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma (2009) (94)
- The tumor suppressor gene rap1GAP is silenced by mir-101-mediated EZH2 overexpression in invasive squamous cell carcinoma (2011) (94)
- Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo (2004) (93)
- Precision oncology in the age of integrative genomics (2018) (93)
- The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. (2003) (92)
- Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC) (2018) (92)
- Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. (2011) (91)
- RhoC Induces Differential Expression of Genes Involved in Invasion and Metastasis in MCF10A Breast Cells (2004) (90)
- The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication (1997) (89)
- Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. (2016) (89)
- The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. (2014) (88)
- ETS rearrangements and prostate cancer initiation (2009) (87)
- Estrogen receptor mutations and their role in breast cancer progression (2014) (87)
- Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. (2007) (87)
- Prostate cancer cell–stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases (2014) (86)
- Transcriptome Sequencing Identifies PCAT-1, a Novel lincRNA Implicated in Prostate Cancer Progression (2011) (86)
- A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer12 (2014) (86)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (85)
- Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. (2020) (84)
- Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer (2014) (84)
- ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate: Implications for the Distinction Between Intraductal Carcinoma of the Prostate and Cribriform High-grade Prostatic Intraepithelial Neoplasia (2010) (84)
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment (2020) (84)
- The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. (2011) (84)
- In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. (1993) (84)
- Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target. (2012) (83)
- Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. (2012) (83)
- CD95 (APO-1/Fas)-associating signalling proteins. (1996) (82)
- The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression (2014) (82)
- Development of a Sensitive Microarray Immunoassay and Comparison With Standard Enzyme-Linked Immunoassay for Cytokine Analysis (2004) (82)
- Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories. (2016) (81)
- Bioinformatics approaches in the study of cancer. (2007) (80)
- The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer (2010) (79)
- An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer (2009) (79)
- Feature selection and molecular classification of cancer using genetic programming. (2007) (78)
- A proteogenomic portrait of lung squamous cell carcinoma (2021) (77)
- A Dual Role for Receptor-interacting Protein Kinase 2 (RIP2) Kinase Activity in Nucleotide-binding Oligomerization Domain 2 (NOD2)-dependent Autophagy* (2012) (77)
- Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity (2007) (77)
- Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. (2012) (77)
- Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. (2017) (76)
- Dynamic recruitment of single RNAs to processing bodies depends on RNA functionality (2018) (76)
- RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. (2009) (76)
- Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. (2015) (75)
- Galanin modulates the neural niche to favour perineural invasion in head and neck cancer (2015) (74)
- Reconstructing targetable pathways in lung cancer by integrating diverse omics data (2013) (74)
- Oncogenic gene fusions in epithelial carcinomas. (2009) (74)
- Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients (2011) (74)
- Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. (2018) (73)
- Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. (2012) (72)
- Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response (2021) (71)
- Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. (2004) (71)
- Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. (2005) (70)
- Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. (2016) (68)
- Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. (2012) (68)
- Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. (2018) (68)
- From Bytes to Bedside: Data Integration and Computational Biology for Translational Cancer Research (2007) (68)
- Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer (2012) (68)
- KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation. (2014) (67)
- Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. (2019) (67)
- Elevated α-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer (2004) (67)
- Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors (2021) (66)
- Activating ESR 1 mutations in hormone-resistant metastatic breast cancer (2013) (66)
- Rational approach to implementation of prostate cancer antigen 3 into clinical care (2009) (66)
- Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. (2008) (66)
- Translating genomics for precision cancer medicine. (2014) (65)
- HIV infection reveals widespread expansion of novel centromeric human endogenous retroviruses (2013) (65)
- Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer (2016) (65)
- Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer (2017) (65)
- Noncoding RNAs and Cancer (2013) (65)
- Cisplatin Induces Bmi1 and Enhances the Stem Cell Fraction in Head and Neck Cancer (2015) (65)
- Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency (2019) (65)
- Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays (2018) (64)
- Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. (2020) (64)
- Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. (2003) (64)
- Humoral Response Profiling Reveals Pathways to Prostate Cancer Progression*S (2008) (64)
- Role of transcriptional corepressor CtBP1 in prostate cancer progression. (2012) (64)
- ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. (2010) (64)
- A Latent Variable Approach for Meta-Analysis of Gene Expression Data from Multiple Microarray Experiments (2007) (63)
- Integrative biology of prostate cancer progression. (2006) (63)
- Precision medicine in pediatric oncology: Lessons learned and next steps (2017) (63)
- Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. (2016) (63)
- Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19 (2021) (62)
- The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc (2020) (62)
- Transcriptomic heterogeneity in multifocal prostate cancer. (2018) (62)
- Bioinformatics Strategies for Translating Genome‐Wide Expression Analyses into Clinically Useful Cancer Markers (2004) (62)
- Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. (2009) (61)
- The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease. (2013) (60)
- The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. (2017) (60)
- Exploring Clinical Associations Using ‘-Omics’ Based Enrichment Analyses (2009) (60)
- Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. (2012) (59)
- Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer (2015) (59)
- A clonal expression biomarker associates with lung cancer mortality (2019) (59)
- De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome. (2016) (59)
- Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2′,5′-oligoadenylate synthetase from prostate cancer cells (2006) (59)
- Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. (2020) (57)
- CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac (2008) (57)
- The Unfolded Protein Response Modulates Toxicity of the Expanded Glutamine Androgen Receptor* (2005) (57)
- MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer (2016) (56)
- HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. (2013) (56)
- Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. (2014) (56)
- Prostatic preneoplasia and beyond. (2008) (55)
- Molecular markers of prostate cancer. (2006) (54)
- Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition (2006) (53)
- Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer (2021) (53)
- Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. (2008) (52)
- Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. (2004) (52)
- TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. (2011) (52)
- α-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis (2005) (52)
- A Comparison of Single Molecule and Amplification Based Sequencing of Cancer Transcriptomes (2011) (52)
- CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy (2019) (52)
- Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. (2010) (52)
- Proteomic Interrogation of Androgen Action in Prostate Cancer Cells Reveals Roles of Aminoacyl tRNA Synthetases (2009) (52)
- Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. (2013) (51)
- Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer (2019) (50)
- Whole transcriptome amplification for gene expression profiling and development of molecular archives. (2006) (50)
- Molecular Pathways: Targeting ETS Gene Fusions in Cancer (2014) (49)
- The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. (2018) (49)
- Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk (2012) (49)
- Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039)) (2018) (48)
- AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma (2008) (48)
- Eigengene-based linear discriminant model for tumor classification using gene expression microarray data (2006) (48)
- Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma (2013) (47)
- Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer (2016) (47)
- Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. (2020) (46)
- Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. (2006) (46)
- SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing. (2012) (46)
- Translocations in epithelial cancers. (2009) (45)
- Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes (2021) (45)
- Multivalent proteins rapidly and reversibly phase-separate upon osmotic cell volume change (2019) (45)
- Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target (2012) (45)
- Protein microarrays using liquid phase fractionation of cell lysates (2003) (45)
- The Discovery of Common Recurrent Transmembrane Protease Serine 2 (TMPRSS2)-Erythroblastosis Virus E26 Transforming Sequence (ETS) Gene Fusions in Prostate Cancer: Significance and Clinical Implications (2009) (45)
- Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. (2014) (45)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (44)
- Urine TMPRSS 2 : ERG Plus PCA 3 for Individualized Prostate Cancer Risk Assessment (2016) (44)
- The DNA methylation landscape of advanced prostate cancer (2020) (44)
- Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas (2018) (43)
- Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. (2016) (43)
- High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. (2002) (43)
- MechRNA: prediction of lncRNA mechanisms from RNA–RNA and RNA–protein interactions (2018) (43)
- Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer (2006) (43)
- Evaluation of Tissue PCA3 Expression in Prostate Cancer by RNA in situ Hybridization - A Correlative Study with Urine PCA3 and TMPRSS2-ERG (2013) (43)
- Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist (2014) (42)
- miR-34a directly targets tRNAiMet precursors and affects cellular proliferation, cell cycle, and apoptosis (2018) (42)
- The discovery and application of gene fusions in prostate cancer (2008) (42)
- Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia (2013) (42)
- Molecular and Immunohistochemical Characterization Reveals Novel BRAF Mutations in Metanephric Adenoma (2015) (41)
- Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. (2003) (41)
- Development of an Internally Controlled Antibody Microarray* (2005) (41)
- Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy (2017) (40)
- miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression (2017) (40)
- Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. (2021) (40)
- HOXB13 G84E–related Familial Prostate Cancers: A Clinical, Histologic, and Molecular Survey (2014) (40)
- The Death Inhibitory Molecules CED-9 and CED-4L Use a Common Mechanism to Inhibit the CED-3 Death Protease* (1998) (40)
- Outlier kinase expression by RNA sequencing as targets for precision therapy. (2013) (39)
- A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. (2008) (39)
- CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. (2020) (39)
- Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer (2019) (39)
- The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. (2018) (38)
- Pathway analysis reveals functional convergence of gene expression profiles in breast cancer (2008) (38)
- “Topological Significance” Analysis of Gene Expression and Proteomic Profiles from Prostate Cancer Cells Reveals Key Mechanisms of Androgen Response (2010) (37)
- The molecular fingerprint of lung inflammation after blunt chest trauma (2015) (37)
- HRAS mutations are frequent in inverted urothelial neoplasms. (2014) (37)
- Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer (2017) (37)
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma (2020) (36)
- Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. (2013) (36)
- Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. (2018) (36)
- Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. (2014) (36)
- Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation. (2008) (36)
- Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. (2009) (36)
- KRAS Engages AGO2 to Enhance Cellular Transformation. (2016) (36)
- Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. (2004) (35)
- Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration‐resistant prostate cancer (2014) (35)
- Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences (2011) (35)
- TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. (2020) (35)
- MicroRNA expression patterns in indeterminate inflammatory bowel disease (2013) (34)
- Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer1 (2016) (34)
- RNA-Seq Accurately Identifies Cancer Biomarker Signatures to Distinguish Tissue of Origin1 (2014) (34)
- The registry case finding engine: an automated tool to identify cancer cases from unstructured, free-text pathology reports and clinical notes. (2007) (34)
- The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development (2020) (33)
- Two-pass alignment improves novel splice junction quantification (2015) (33)
- Accelerating precision medicine in metastatic prostate cancer (2020) (33)
- Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature (2018) (32)
- TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort (2007) (32)
- The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells. (2012) (32)
- Clinical validation of the Tempus xO assay (2018) (32)
- Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion☆ (2020) (32)
- Variable reference alignment: an improved peak alignment protocol for NMR spectral data with large intersample variation. (2012) (32)
- The role of the histone H3 variant CENPA in prostate cancer (2020) (31)
- Next‐generation sequencing in precision oncology: Patient understanding and expectations (2019) (30)
- Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications (2017) (30)
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. (2018) (30)
- Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay (2017) (29)
- Novel RNA Hybridization Method for the In Situ Detection of ETV1, ETV4, and ETV5 Gene Fusions in Prostate Cancer (2014) (29)
- Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. (2020) (28)
- Systematic, evidence-based discovery of biomarkers at the NCI (2012) (28)
- Chromosomal aberrations in solid tumors. (2010) (27)
- Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes (2017) (27)
- Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. (2014) (27)
- Evidence of recurrent gene fusions in common epithelial tumors. (2006) (27)
- Corrigendum: TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer (2016) (27)
- Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. (2013) (27)
- Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes (2020) (26)
- The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer (2014) (26)
- Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer (2018) (26)
- Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. (2006) (26)
- Physician Experiences and Understanding of Genomic Sequencing in Oncology (2018) (26)
- Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer (2017) (26)
- Applications of genetic programming in cancer research. (2009) (26)
- Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer (2021) (26)
- Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification (2017) (25)
- VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney (2018) (25)
- RNA-Seq unleashed (2011) (25)
- Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, AMACR, and CK903) and GATA-3 (2014) (24)
- Differential proteomic alterations between localised and metastatic prostate cancer (2006) (24)
- Differential phosphoprotein mapping in cancer cells using protein microarrays produced from 2-D liquid fractionation. (2006) (24)
- Disruptive events in the life of prostate cancer. (2011) (24)
- Next-Generation Sequencing Identifies the Danforth's Short Tail Mouse Mutation as a Retrotransposon Insertion Affecting Ptf1a Expression (2013) (24)
- Characterization of TMPRSS 2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer (2008) (23)
- ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches (2009) (23)
- Transcriptome Analysis of HER 2 Reveals a Molecular Connection to Fatty Acid Synthesis 1 (2002) (23)
- Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. (2014) (22)
- Development of selected reaction monitoring‐MS methodology to measure peptide biomarkers in prostate cancer (2010) (22)
- Antibody‐independent targeted quantification of TMPRSS2‐ERG fusion protein products in prostate cancer (2014) (21)
- Next generation sequencing of extraskeletal myxoid chondrosarcoma (2017) (21)
- MetaboID: a graphical user interface package for assignment of 1H NMR spectra of bodyfluids and tissues. (2013) (21)
- Dynamic changes during the treatment of pancreatic cancer (2018) (21)
- AGTR1 as a therapeutic target in ER-positive and ERBB-negative breast cancer cases (2009) (21)
- Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. (2016) (21)
- Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer12 (2016) (20)
- Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer (2019) (20)
- Prostate Cancer Expression Profiles Reveals Pathway Dysregulation in Meta-Analysis of Microarrays : Interstudy Validation of Gene Updated (2002) (20)
- ESR 1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients (2015) (20)
- Heat Shock Protein Beta-1 Modifies Anterior to Posterior Purkinje Cell Vulnerability in a Mouse Model of Niemann-Pick Type C Disease (2016) (20)
- Using protein microarrays to study cancer. (2002) (20)
- LBA20ANTITUMOUR ACTIVITY OF THE PARP INHIBITOR OLAPARIB IN UNSELECTED SPORADIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN THE TOPARP TRIAL (2014) (19)
- Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. (2017) (19)
- Rapid molecular assays to study human centromere genomics (2017) (19)
- Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22‐gene genomic classifier (2019) (19)
- An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development (2017) (19)
- miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers (2013) (18)
- The Enzymatic Activity of Apoptosis-inducing Factor Supports Energy Metabolism Benefiting the Growth and Invasiveness of Advanced Prostate Cancer Cells* (2012) (18)
- Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data. (2017) (18)
- Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. (2010) (18)
- rSeqNP: a non-parametric approach for detecting differential expression and splicing from RNA-Seq data (2015) (18)
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factors in Prostate Cancer (2006) (18)
- A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature (2013) (17)
- Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event (2017) (17)
- Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)--A University of Chicago phase II consortium tria (2016) (17)
- Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma (2020) (17)
- MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data (2018) (17)
- Erratum: Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine (American Journal of Human Genetics (2016) 98(6) (1067–1076) (S0002929716301069) (10.1016/j.ajhg.2016.04.011)) (2016) (17)
- A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine (2016) (17)
- Integrating Biomedical Knowledge to Model Pathways of Prostate Cancer Progression (2007) (17)
- Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. (2018) (17)
- Global genomics project unravels cancer’s complexity at unprecedented scale (2020) (16)
- Erratum: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort (Oncogene (2007) 26, (4596-4599) DOI: 10.1038/sj.onc.1210237) (2007) (16)
- Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer (2018) (15)
- The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell (2014) (15)
- DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway (2019) (15)
- Molecular profiling of ETS and non‐ETS aberrations in prostate cancer patients from northern India (2015) (15)
- Use of the MyProstateScore (MPS) Test to Rule Out Clinically-Significant Cancer: Validation of a Straightforward Clinical Testing Approach. (2020) (15)
- An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status. (2008) (15)
- Androgen receptor activation results in metabolite signatures of an aggressive prostate cancer phenotype: an NMR-based metabonomics study (2012) (15)
- Prostate cancer biomarkers: a current perspective (2003) (15)
- BETs abet Tam-R in ER-positive breast cancer (2014) (14)
- Comprehensive Immunophenotypic Characterization of Adult and Fetal Testes, the Excretory Duct System, and Testicular and Epididymal Appendages (2016) (14)
- Role of BET proteins in castration-resistant prostate cancer. (2016) (14)
- Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
- BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma (2018) (14)
- Protein microarrays: a powerful tool to study cancer. (2002) (14)
- Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series (2019) (14)
- Genetic diversity of NDUFV1-dependent mitochondrial complex I deficiency (2018) (14)
- The Potential of Circular RNAs as Cancer Biomarkers (2020) (14)
- Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry (2018) (13)
- Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. (2018) (13)
- Internet-based profiler system as integrative framework to support translational research (2005) (13)
- Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy. (2019) (13)
- Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas (2021) (13)
- Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series (2014) (13)
- Characterization of SARS-CoV-2 and host entry factors distribution in a COVID-19 autopsy series (2021) (13)
- The utility of upper urinary tract urine cytology before and after application of the Paris system (2019) (13)
- Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy (2020) (13)
- Competing for enhancers: PVT1 fine-tunes MYC expression (2018) (12)
- Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program. (2018) (12)
- Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply. (2021) (12)
- De novo neuroendocrine transdifferentiation in primary prostate cancer–a phenotype associated with advanced clinico-pathologic features and aggressive outcome (2021) (12)
- CD38 in Advanced Prostate Cancers (2021) (12)
- Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis (2017) (12)
- Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element (2020) (12)
- Pathway-directed weighted testing procedures for the integrative analysis of gene expression and metabolomic data. (2012) (11)
- Metabolism drives macrophage heterogeneity in the tumor microenvironment (2022) (11)
- Of mice and men: cancer gene discovery using comparative oncogenomics. (2006) (11)
- A novel ATXN1-DUX4 fusion expands the spectrum of ‘CIC-rearranged sarcoma’ of the CNS to include non-CIC alterations (2021) (11)
- A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation. (1999) (11)
- PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates (2020) (11)
- Covariate adjustment in the analysis of microarray data from clinical studies (2004) (11)
- DNA Microarrays: Implications for Clinical Medicine (2002) (11)
- Preclinical Evaluation of 11C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer (2017) (11)
- Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. (2013) (10)
- Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program (2020) (10)
- Nrdp 1-Mediated Regulation of ErbB 3 Expression by the Androgen Receptor in Androgen-Dependent but not Castrate-Resistant Prostate Cancer Cells (2010) (10)
- NMR-Based Metabolomic Profiling of Urine: Evaluation for Application in Prostate Cancer Detection (2019) (10)
- A systems approach to model metastatic progression. (2006) (10)
- TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma (2021) (10)
- Erratum: Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer (Cancer Cell (2017) 31(4) (532–548.e7)(S1535610817300600)(10.1016/j.ccell.2017.02.017)) (2017) (10)
- Abstract 4681: Inhibition of poly (ADP-ribose) polymerase-1 (PARP-1) as a strategy for targeted therapy in Ewing's sarcoma (2012) (10)
- Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells (2016) (10)
- Activating mutations of the oncogene EZH2 in cutaneous melanoma revealed by next generation sequencing (2014) (9)
- AGO2 promotes tumor progression in KRAS-driven mouse models of non–small cell lung cancer (2021) (9)
- Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas (2021) (9)
- Direct cellular reprogramming enables development of viral T antigen–driven Merkel cell carcinoma in mice (2022) (9)
- Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. (2017) (9)
- Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257)) (2019) (9)
- aBETting therapeutic resistance by Wnt signaling (2015) (9)
- A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium. (2008) (9)
- Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile (2019) (8)
- Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology (2018) (8)
- Quantitative Determination of Expression of the Prostate Cancer Protein α-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA) (2004) (8)
- Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics (2016) (8)
- Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. (2019) (8)
- Active surveillance for prostate cancer: the role of the pathologist. (2015) (8)
- A randomized phase II trial of abiraterone, olaparib or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects. (2017) (8)
- TSLP-Driven Chromatin Remodeling and Trained Systemic Immunity after Neonatal Respiratory Viral Infection (2021) (8)
- Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults. (2017) (8)
- FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST (2009) (8)
- Abstract 4707: Discovery and characterization of PCAT-1, a novel lincRNA implicated in prostate cancer tumorigenesis (2011) (7)
- G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer (2021) (7)
- Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology (2015) (7)
- Incorporating genetic counseling into clinical care for children and adolescents with cancer. (2016) (7)
- 297 FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST (2009) (7)
- Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature (2019) (7)
- Noninvasive Detection of TMPRSS 2 : ERG Fusion Transcripts in the Urine of Men with Prostate Cancer 1 (2014) (7)
- Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial. (2015) (7)
- Corrigendum: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression (2013) (7)
- Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements—a clinicopathologic and genomic sequencing-based discussion (2019) (7)
- Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. (2016) (7)
- Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer (2008) (7)
- A subset of solitary fibrous tumors express nuclear PAX8 and PAX2: a potential diagnostic pitfall. (2016) (7)
- RNA identity crisis: hepatitis B walks the LINE. (2014) (6)
- Immunotherapy for Conjunctival Squamous Cell Carcinoma with Orbital Extension. (2020) (6)
- KLF 6-SV 1 overexpression accelerates human and mouse prostate cancer progression and metastasis (2018) (6)
- Making and Using DNA Microarrays : A Short Course at Cold Spring Harbor Laboratory (2000) (6)
- A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer (2021) (6)
- Oculus: faster sequence alignment by streaming read compression (2012) (6)
- Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer (2021) (6)
- Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer (2015) (6)
- IMPACT: Immunotherapy in patients with metastatic cancers and CDK12 mutations. (2019) (6)
- Pediatric craniopharyngioma in association with familial adenomatous polyposis (2019) (6)
- The histone methyltransferase Ezh 2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease (2013) (6)
- Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. (2004) (6)
- A transcriptomic model for homologous recombination deficiency in prostate cancer (2021) (5)
- Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy (NAC) in urothelial carcinoma. (2015) (5)
- Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center. (2015) (5)
- Insights into Chinese prostate cancer with RNA-seq (2012) (5)
- Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. (2021) (5)
- Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (5)
- Mutations predictive of hyperactive Ras signaling correlate with inferior survival across high-risk pediatric acute leukemia. (2020) (5)
- Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. (2014) (5)
- Trisomy 12-associated, t(11;14)-negative mature B-cell leukemia with gene expression profile resembling mantle cell lymphoma (2006) (5)
- Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study (2017) (5)
- Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer? (2020) (5)
- Viral Status Predicts Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma. (2021) (5)
- Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections (2018) (4)
- Rare Presentation of Metastatic Cystic Trophoblastic Tumor in a Patient Without Prior Chemotherapy (2017) (4)
- Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC. (2018) (4)
- Oncologists' Use of Genomic Sequencing Data to Inform Clinical Management. (2018) (4)
- Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC). (2020) (4)
- Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. (2023) (4)
- to stimulate chemokine production and neutrophil recruitment in vivo (2006) (4)
- Case Study: Systematic Detection and Prioritization of Gene Fusions in Cancer by RNA-Seq: A DIY Toolkit. (2020) (4)
- Gene Fusion Markup Language: a prototype for exchanging gene fusion data (2012) (4)
- Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: Data from NCI 9012, a randomized ETS fusion-stratified phase II trial. (2014) (4)
- Cancer SLC43A2 alters T cell methionine metabolism and histone methylation (2020) (4)
- Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma1 (2019) (4)
- Targeting Estrogen Receptor (ER) Mutations for Treatment of Endocrine Therapy Resistance in Breast Cancer (2016) (4)
- CRISPRs in the human genome are differentially expressed between malignant and normal adjacent to tumor tissue (2022) (3)
- URINE PROSTATE CANCER GENE 3 ASSAY FOR RISK STRATIFICATION AND IMPROVED PREDICTION FOR PROSTATE CANCER (2008) (3)
- Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need. (2021) (3)
- RNA-seq of human T cells after hematopoietic stem cell transplantation identifies Linc00402 as a regulator of T cell alloimmunity (2021) (3)
- Targeting ESR1 mutation–induced transcriptional addiction in breast cancer with BET inhibition (2022) (3)
- Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 (2022) (3)
- TERT Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract (2022) (3)
- Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series (2020) (3)
- Identification and Validation of Intrinsic Subtypes of Prostate Cancer. (2016) (3)
- Abstract PD6-1: The long noncoding RNA M41 promotes aggressiveness and tamoxifen resistance in ER-positive breast cancers (2015) (3)
- Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci (2022) (3)
- Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. (2022) (3)
- Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study (2020) (3)
- Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium ‘Breast Cancer – the Development and Validation of New Therapeutics’ (2005) (3)
- BETting on a new prostate cancer treatment (2014) (3)
- Advances in Biomarkers for Prostate Diseases (2006) (3)
- Connection to Fatty Acid Synthesis Transcriptome Analysis of HER 2 Reveals a Molecular Updated (2002) (2)
- The PI3K/AKT pathway in renal (clear cell) carcinoma via meta-analysis of expression microarrays (2005) (2)
- Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy (2021) (2)
- VISION: Oncomine and cabig advance cancer bioinformatics (2005) (2)
- 1436: Comprehensive Assessment of TMPRSS2 and ETS Family Gene Aberrations in Clinically Localized Prostate Cancer (2007) (2)
- Role of Transcriptional Corepressor CtBP1 in Prostate (2012) (2)
- Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. (2021) (2)
- Tomlins et al. reply (2009) (2)
- Improved prediction of disease-free survival in tamoxifen-treated patients using an expression signature of estrogen-regulated genes as compared to progesterone receptor. (2006) (2)
- Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. (2015) (2)
- Abstract 2458: The androgen receptor-regulated lncRNA landscape reveals a role forARlnc1in prostate cancer progression (2018) (2)
- Nomination and validation of the long noncoding RNA SChLAP1 as a risk factor for metastatic prostate cancer progression: a multi-institutional high-throughput analysis (2015) (2)
- Erratum: TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer (Nature Communications (2014) 5 (4527) DOI: 10.1038/ncomms5527) (2016) (2)
- Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors (2023) (2)
- 2121 URINE MEASUREMENT OF TMPRSS2:ERG FOR THE EARLY DETECTION OF SIGNIFICANT PROSTATE CANCER (2010) (2)
- OncoMine and caBIG advance cancer bioinformatics (2005) (2)
- Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia (2015) (2)
- Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer. (2016) (2)
- Investigating the long noncoding RNA SChLAP1 as a prognostic tissue and urine biomarker in prostate cancer. (2015) (2)
- MICHIGAN PROSTATE SCORE (MIPS): AN ANALYSIS OF A NOVEL URINARY BIOMARKER PANEL FOR THE PREDICTION OF PROSTATE CANCER AND ITS IMPACT ON BIOPSY RATES: PD07‐03 (2017) (2)
- Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma (2022) (2)
- α-Methylacyl coenzyme A racemase as a marker for prostate cancer. Authors' reply (2002) (2)
- Abstract 4969: Exosomal RNA based liquid biopsy detection of androgen receptor variant 7 in plasma from prostate cancer patients (2016) (2)
- Clinical application of next generation sequencing in lymphoma (2019) (2)
- GENT-44. LOWERED H3K27me3 AND DNA HYPOMETHYLATION DEFINE POORLY PROGNOSTIC PEDIATRIC POSTERIOR FOSSA EPENDYMOMAS (2016) (2)
- The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma (2022) (2)
- Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients (2019) (2)
- Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin (2015) (2)
- Recurrent gene fusions in prostate cancer: ETV1 class of fusions (2007) (2)
- Abstract 541: The role of long noncoding RNA SChLAP1 in prostate cancer (2014) (2)
- The Registry Case Finding Engine (CaFE): An automated approach for cancer patient identification from unstructured, free-text pathology reports. (2006) (2)
- Androgen regulation of prostate cancer gene fusions (2009) (2)
- Abstract 5342: Somatic bi-allelic loss of TSC genes in eosinophilic solid and cystic renal cell carcinoma (ESC RCC) (2018) (2)
- Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039. (2015) (2)
- Analysis of the androgen receptor–regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression (2018) (2)
- Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study (2021) (2)
- Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer (2022) (2)
- Oculus: faster sequence alignment by streaming read compression (2012) (1)
- Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice. (2020) (1)
- chromatin modification A role for the MLL fusion partner ENL in transcriptional elongation and (2013) (1)
- Abstract 956: An essential role forArgonaute 2in EGFR-KRAS signaling in pancreatic cancer development (2019) (1)
- Genetic polymorphisms to predict progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone therapy: Results from the NCI 9012 trial. (2017) (1)
- Are oncologists using genome sequencing results to inform patient care (2015) (1)
- PARP inhibition reverses radiation resistance conferred by ETS fusions in prostate cancer. (2011) (1)
- miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers (2013) (1)
- Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice (2020) (1)
- Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM) (2020) (1)
- Acknowledgment of Guest Editors, 2019 (2019) (1)
- Abstract 5795: Functional and mechanistic interrogation of BET Bromodomain degraders for the treatment of metastatic castration resistant prostate cancer (2017) (1)
- Amendment history : Erratum ( April 2018 ) Host expression of PD-L 1 determines efficacy of PD-L 1 pathway blockade – mediated tumor regression (2018) (1)
- Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol (2017) (1)
- Abstract 2808: Characterization of KRAS rearrangements in metastatic prostate cancer (2011) (1)
- Gene Fusion Markup Language: a prototype for exchanging gene fusion data (2012) (1)
- ERG EXPRESSION VARIES IN DIFFERENT ISOFORMS OF TMPRSS2:ERG GENE FUSION IN PROSTATE CANCER (2008) (1)
- MP26-12 USE OF THE MYPROSTATESCORE (MPS) TEST FOR RISK STRATIFICATION IN MEN WITH A PREVIOUS NEGATIVE BIOPSY: INITIAL VALIDATION OF A STRAIGHTFORWARD TESTING APPROACH (2021) (1)
- Abstract 4153: Therapeutic targeting autophagy to sensitize cancer immunotherapy in various cancer types (2019) (1)
- Abstract 3383: Circular RNAs as non-invasive diagnostic biomarkers for prostate cancer (2022) (1)
- Abstract 983: Integrative analysis of androgen receptor regulated long non-coding RNA in prostate cancer (2016) (1)
- Identification and Validation of PCAT 14 as Prognostic Biomarker in Prostate Cancer 1 (2016) (1)
- Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways (2022) (1)
- α-Methylacyl Coenzyme A Racemase as a Marker for Prostate Cancer—Reply (2002) (1)
- Therapeutic reversal of prenatal pontine ID1 signaling in DIPG (2021) (1)
- Abstract 2815: Urine TMPRSS2:ERG for prostate cancer risk stratification in men with elevated serum PSA (2011) (1)
- Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. (2021) (1)
- The Oncomine Cancer Research Panel, a scalable next-generation sequencing system for relevant somatic variant assessment in solid tumors. (2015) (1)
- The long tail of oncogenic drivers in prostate cancer (2018) (1)
- Abstract 899: TMPRSS2:ERG urine test identifies Gleason score upgrading and significant prostate cancer (2011) (1)
- Abstract 3038: Bridging the gap between NGS data and its usability: cancer gene discovery through massive-scale transcriptomic analyses and development of a powerful web-tool for dissemination of these findings (2017) (1)
- The long tail of significantly mutated genes in prostate cancer. (2017) (1)
- Characterization of Protein (2SC) Succination as a Biomarker for Fumarate Hydratase-deficient Renal Cell Carcinoma. (2022) (1)
- TMPRSS2-ERG FUSION PROSTATE CANCER PREVALENCE, ASSOCIATION WITH PSA DENSITY, AND HISTOLOGIC FEATURES IN A MULTI-CENTER U.S. COHORT OF MEN UNDERGOING PROSTATE BIOPSY (2008) (1)
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer (2013) (1)
- Abstract 1192: Glutamic acid and glutaminolysis mark aggressive tumorigenesis in head and neck squamous cell carcinoma (2015) (1)
- Bi-allelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney (1)
- Abstract 4399: Exploring the postmitotic roles of STAG2 mutations in solid tumors (2019) (1)
- A Tissue-specific Long Noncoding RNA Controls Homologous Recombination in Prostate Cancer (2012) (1)
- Genomic Landscape and Clinical Features of Triple‐Negative Myelofibrosis: MPN‐285 (2018) (1)
- MyProstateScore in men considering repeat biopsy: validation of a simple testing approach. (2022) (1)
- Identification of clinically actionable pharmacogenetic variants during tumor genetic profiling in pediatric cancer patients. (2016) (1)
- Abstract 5214: Reconstructing targetable pathways in KRAS dependent lung cancer by integrating transcriptome, proteome and phosphoproteome. (2013) (1)
- TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. (2020) (1)
- A SLAMS dunk for cancer regulators (2006) (1)
- Noninvasive identification of lineage-specific circular RNA for ER-positive breast cancer. (2020) (1)
- Molecular Characterization of a Rare Case of Bilateral Vitreoretinal T Cell Lymphoma through Vitreous Liquid Biopsy (2021) (1)
- Proteolytic regulation of β-catenin by calpain and potential role in cancer (2004) (1)
- Clinical Sequencing of High-Grade Undifferentiated Sarcomas: A Case Series and Report of an Aggressive Primary Cardiac Tumor With Multiple Oncogenic Drivers. (2020) (1)
- Targeted Radiosensitization of ETS Gene Fusion-Positive Prostate Cancer (2010) (1)
- Diagnostic et traitement du cancer du sein (2007) (1)
- Abstract B39: Long noncoding RNA PCAT14/PRCAT104; A prognostic biomarker in prostate cancer (2016) (1)
- Comprehensive molecular profiling of pretreatment metastatic castration resistant prostate cancer (CRPC): Secondary data from NCI 9012, a randomized ETS fusion-stratified phase II trial. (2014) (1)
- Abstract 475: Role of microRNA-34a in regulating oncoprotein STMN1 (2017) (1)
- PubMed QUEST: The PubMed Query Search Tool. An informatics tool to aid cancer centers and cancer investigators in searching the PubMed databases (2006) (1)
- Identification of gene copy number and whole-genome methylation changes associated with lethal metastatic castration-resistant prostate cancer (CRPC). (2011) (1)
- Argonaute 2 modulates EGFR–RAS signaling to promote mutant HRAS and NRAS-driven malignancies (2022) (1)
- Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity (2018) (1)
- Empirical Bayes Identication of Tumor Progression Genes from Microarray Data (2007) (1)
- Advances in Brief The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression (2004) (1)
- The Long Noncoding RNA PCAT-1 Promotes Prostate Cell Proliferation Through Posttranscriptional Stabilization of the cMyc Oncogene (2014) (1)
- Abstract 953: Mechanistic rationale for inhibition of Poly(ADP-Ribose) Polymerase in ETS gene fusion positive prostate cancer (2011) (1)
- Defining cancer growth beyond the mitotic index (2022) (1)
- Estrogen receptor mutations and their role in breast cancer progression (2014) (1)
- 2158 COMBINING TMPRSS2:ERG AND PCA3 IN POST-DRE URINE WITH SERUM PSA TO IDENTIFY PROSTATE BIOPSY CANDIDATES: DEVELOPMENT AND VERIFICATION OF A CLINICALLY PRACTICAL ALGORITHM (2010) (0)
- Abstract 4011: Preferential cytotoxicity of ESK981 in neuroendocrine prostate cancer (2023) (0)
- Purification of an MLL Partner Associated Complex (MPAC) Suggests a Common Role for MLL Fusion Partners in Transcriptional Elongation. (2006) (0)
- Landscape of gene fusions in epithelial cancers: seq and ye shall find (2015) (0)
- SPATA: An Accurate GUI Tool forDe NovoTranscriptome Assembly (2010) (0)
- Antibody-Based Detection of ERG Rearrangement-Positive (2010) (0)
- Abstract 2936: Ago2 induces Kras signaling and promotes tumor progression in mouse models of lung adenocarcinoma (2021) (0)
- Abstract 2992: The landscape of long non-coding RNAs in cancer (2015) (0)
- Abstract 2577: AGO2 interaction limits wild type RAS activation yet essential for disease progression in oncogenic KRAS driven cancers (2020) (0)
- CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA (2020) (0)
- 360 CAD, a Nucleotide Synthesis Enzyme, Inhibits NOD2 Anti-Bacterial Function in Human Intestinal Epithelial Cells (2012) (0)
- Characterization of urothelial carcinoma with seminal vesicle involvement in locally advanced bladder cancer. (2016) (0)
- Global genomics project unravels cancer’s complexity at unprecedented scale (2020) (0)
- Abstract IA07: The application of integrative sequencing for precision oncology (2016) (0)
- Dissecting the molecular signatures underlying hybrid oncocytic tumors in Birt-Hogg-Dubé syndrome. (2023) (0)
- A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors (2018) (0)
- Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer (2019) (0)
- Profiling gene expression in atherosclerosis using DNA microarrays (2002) (0)
- Abstract 2483: An antibody-independent, complementary SRM strategy for ultrasensitive and multiplexed quantification of cancer biomarker candidates (2014) (0)
- Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
- Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer. (2023) (0)
- Pdct-03. Clinically Integrated Sequencing In The Management Of Children With High-Risk Brain Tumors (2016) (0)
- Clinical Protocol Personalized Medicine Based on Molecular Profiling of Pediatric and Young Adult Patients with Cancer ( HUM 00046018 ) (2015) (0)
- Abstract P3-05-01: Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC) (2016) (0)
- Abstract 4986: Kinome analysis of cancers by high-throughput transcriptome sequencing: Ideas in personalized medicine (2011) (0)
- Systematic, evidence-based discovery of biomarkers at the NCI (2012) (0)
- Abstract 3523: A systematic comparison of molecular features shared by H3K27-altered diffuse midline gliomas and posterior fossa A ependymomas (2023) (0)
- Real-world application of next generation sequencing to guide therapeutic options in lymphoma. (2019) (0)
- Abstract 2549: A long non-coding RNA regulates the androgen receptor and mediates prostate cancer progression (2017) (0)
- Pezcoller Symposium : Cancers Driven by Hormones (2015) (0)
- Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling (2017) (0)
- On the other hand , CD 28 has a major role in providing a (1998) (0)
- Characterization of Intercalated Cell Markers KIT and LINC01187 in Chromophobe Renal Cell Carcinoma and Other Renal Neoplasms. (2022) (0)
- Abstract 4982: Oncogenic role ofTHOR, a conserved cancer/testis long noncoding RNA (2018) (0)
- Abstract A026: Expression of fibroblast growth factor receptor 1 isoforms and activation of different pathways in prostate cancer progression (2018) (0)
- Abstract 238: Androgen insensitivity syndrome germline loss-of-function mutations in the androgen receptor that acquire somatic gain-of-function in prostate cancer (2016) (0)
- Abstract 611: Assessment of tumor mutation burden and microsatellite instability by single-cell circulating tumor cell genomic profiling (2022) (0)
- Abstract 5492: Preclinical study of the PARP inhibitor ABT-888 in metastatic prostate cancer (2011) (0)
- Abstract LB-031: A novel model of prostate cancer suggests enzalutamide functions through the immune system to diminish metastatic growth (2019) (0)
- Semiparametric methods for identification of tumor progression genes from microarray data (2004) (0)
- EPCT-07. ID1 IS A KEY TRANSCRIPTIONAL REGULATOR OF DIPG INVASION AND IS TARGETABLE WITH CANNABIDIOL (2021) (0)
- Abstract 1362: Argonaute 2 controls RAS activation in mouse embryonic fibroblasts (2017) (0)
- 785 Slc45a3 Is a Common Ets Family Fusion Partner in Prostate Cancer (2009) (0)
- Highly Recurrent IDH1 Mutations in Prostate Cancer with Psammomatous Calcification (PCWPC). (2023) (0)
- Abstract A05: An in vivo model reveals a role for Argonaute 2 in oncogenic KRAS driven pancreatic cancer initiation (2017) (0)
- Abstract 94: Role of Argonaute 2 in oncogene induced senescence in a pancreatic cancer mouse model (2019) (0)
- Abstract LB-21: Emergence of castration resistant prostate cancer class defined by recurrentERGfusion (2010) (0)
- Abstract 3136: Sample specific outlier kinase expression identified by RNA-Seq provide targets for precision therapy. (2013) (0)
- Abstract ED01-03: Metabolomics of disease progression (2010) (0)
- Abstract 2155: The origins and functional consequences of ETS gene fusions in prostate cancer (2011) (0)
- Expression Profiling of Prostate Cancer Progression (2007) (0)
- ETS rearrangements and prostate cancer initiation Reply (2008) (0)
- Abstract B39: Characterization of the interaction between KRAS and Argonaute 2 (2020) (0)
- Solute carrier family 45 member 3 (slc45a3) and erg family gene fusions in prostate cancer (2008) (0)
- Abstract 2068: Development of a rational triple combination therapy for castration-resistant prostate cancer (2017) (0)
- Abstract 4091: Evaluating the efficacy of a STING agonist in a murine model of prostate cancer (2019) (0)
- Abstract 3487: Identification and validation of PCAT14 as prognostic biomarker in prostate cancer (2017) (0)
- Negative Human Breast Tumors − α Molecular Phenotype of Estrogen Receptor In vivo Induces an In vitro Positive Breast Cancer Cells − α Receptor Activation of Mitogen-Activated Protein Kinase in Estrogen (2006) (0)
- Combining genomic data in human studies (2009) (0)
- Phase 2 trial of immunotherapy in tumors with CDK12 inactivation (IMPACT): Results from cohort A of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) receiving dual immune checkpoint inhibition (ICI). (2022) (0)
- Abstract 4032: Elevated level of let-7a and mir-30c microRNAs in human prostate cancer (2010) (0)
- Molecular Profiling of Experimental Blunt Chest Trauma (2006) (0)
- Abstract B90: Genomic loss of a microRNA leads to overexpression of EZH2 in cancer (2008) (0)
- Mechanism of perineural invasion in head and neck cancer (2014) (0)
- Abstract 3029: An in vivo role for Argonaute 2 in KRAS driven pancreatic cancer (2017) (0)
- Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer (2022) (0)
- Abstract 1278: Elucidating the mechanistic role of ERG in prostate cancer (2020) (0)
- Abstract 4503: Functional CRISPR screen towards identifying novel conserved long noncoding RNAs with oncogenic activity (2019) (0)
- Abstract 5834: Epigenetic re-programming sensitizes prostate cancer cells to anti-androgen therapy (2018) (0)
- Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
- TRIP13 enhances DNA repair to promote treatment resistance in cancer (2014) (0)
- Inhibition of TTK As a Novel Radiosensitization Target in Triple-Negative Breast Cancer That Acts through Impaired Homologous Recombination Repair Efficiency (2019) (0)
- Seminar article Molecular markers of prostate cancer (2006) (0)
- Using microarrays to study apoptosis (1999) (0)
- Abstract 2018: Therapeutic benefit of dual ALK and FAK inhibition in neuroblastoma (2022) (0)
- Impact Of Sequencing Of Androgen Receptor-Signaling Inhibition (ARSI) And Ionizing Radiotherapy (RT) In Prostate Cancer: Importance Of Homologous Recombination (HR) Disruption (2020) (0)
- Identification of clinically significant prostate cancer using a novel multiplexed urine biomarker panel (2019) (0)
- Constitutive Hedgehog/GLI2 signaling drives extracutaneous basaloid squamous cell carcinoma development and bone remodeling. (2021) (0)
- The Histone Methyltransferase Ezh2 Is a Crucial Epigenetic Regulator Of Allogeneic T Cell Responses and Graft-Versus-Host Disease In Mice (2013) (0)
- Abstract A03: Analyses of a prostate cancer patient-derived xenografts series, a resource for translational research (2016) (0)
- ERG Gene Fusions as a Prognostic Tumor Biomarker in Prostate Cancer Patients Treated With Salvage Radiation Therapy (2012) (0)
- Abstract 3127: Comprehensive proteogenomic characterization of rare kidney tumors (2023) (0)
- Abstract 4840: DNA methylation patterns and transcript isoform regulation in prostate cancer (2011) (0)
- PD40-07 CLINICAL DECISION ALGORITHM USING RESTRICTION SPECTRUM IMAGING AND BIOMARKERS TO PREDICT UPGRADING IN ACTIVE SURVEILLANCE (2022) (0)
- Sooryanarayana Varambally , in Cancer Overexpression of Histone Methyltransferase EZH 2 Genomic Loss of microRNA-101 Leads (2009) (0)
- Abstract 166: MicroRNA profiling analysis identify new signature of tumor-promoting M2-type macrophages (2011) (0)
- Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection (2023) (0)
- Abstract 2244: Association of chromosomal instability with poor prognosis in metastatic hormone sensitive and castrate-resistant prostate cancer (2023) (0)
- Abstract 2036: Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors (2023) (0)
- Comprehensive genomic profiling in malignant myoepithelioma to suggest potential alternative diagnosis. (2020) (0)
- The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT). (2020) (0)
- Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
- Pediatric craniopharyngioma in association with familial adenomatous polyposis (2019) (0)
- Abstract 3151: Genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients (2016) (0)
- Identification of Novel PGR-NR4A3 Fusion in Extraskeletal Myxoid Chondrosarcoma and Resultant Patient Benefit From Tamoxifen Therapy (2022) (0)
- Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy. (2022) (0)
- Abstract IA02: The application of integrative sequencing for precision oncology (2015) (0)
- EPND-08. EPIGENETIC H3K27ME3 DEREGULATION IN PEDIATRIC POSTERIOR FOSSA EPENDYMOMAS (2017) (0)
- Abstract 5274: Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients (2022) (0)
- Award Number: W81XWH-11-1-0337 TITLE: Discovery of Novel Gene Elements Associated With Prostate Cancer Progression (2012) (0)
- KLF6-SV1 accelerates prostate cancer progression and metastasis (2008) (0)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (0)
- Gene expression rSeqNP : a non-parametric approach for detecting differential expression and splicing from RNA-Seq data (2015) (0)
- Abstract 4370: Regulation of AGO2-KRAS interaction through epidermal growth factor receptor (2018) (0)
- Recent Advances in the Molecular Biology of Prostate Cancer (2011) (0)
- INTEGRATIVE META-ANALYSIS OF MICROARRAY DATA TO IDENTIFY PROFILES THAT PREDICT BLADDER CANCER OUTCOMES AND PROGRESSION (2008) (0)
- Abstract 3020: An essential role forArgonaute 2in EGFR-KRAS signaling in pancreatic cancer development (2018) (0)
- Abstract B15: The landscape of immune infiltration and mechanisms of immune escape across 500 metastatic cancers (2017) (0)
- Large-scale association analysis of gene signatures links pathways, mechanisms, diseases, and drugs (2007) (0)
- Identification and Validation of the Long Noncoding RNA SChLAP1 as a Prognostic Biomarker in Prostate Cancer (2014) (0)
- Abstract 1447: Identification of an oncogenic germlineKRAStruncating mutation in hereditary cancers (2017) (0)
- Abstract 929: Transcriptome sequencing identifies novel non-coding RNAs associated with prostate cancer progression (2011) (0)
- Discovery of Novel Gene Elements Associated with Prostate Cancer Progression (2014) (0)
- A FIRE-y PAGE in the computational analysis of cancer profiles. (2009) (0)
- Characterization of SPINK 1 in Prostate Cancer (2009) (0)
- Abstract 5719: Clinical response to the PDGFRα inhibitor avapritinib in high-grade glioma patients (2023) (0)
- MP60-02 TRANSCRIPTOMICS CAN PREDICT HOMOLOGOUS RECOMBINATION DEFICIENCY IN PROSTATE CANCER (2021) (0)
- Metastatic prostate cancer diagnosed by fine‐needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates (2022) (0)
- Abstract IA9: Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance (2012) (0)
- Abstract 1056: Inhibition of hexose monophosphate pathway promotes castration resistant prostate cancer (2016) (0)
- MP81-13 UNDERSTANDING THE ROLE OF WNT SIGNALING IN PROSTATE CANCER BONE METASTATIC TROPISM (2019) (0)
- Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas (2023) (0)
- TAMI-42. H3K27M MUTANT GLIOMAS HIJACK A CONSERVED AND CRITICAL METABOLIC PATHWAY USED BY IDH1 MUTANT GLIOMAS TO MAINTAIN THEIR PREFERRED EPIGENETIC STATE (2020) (0)
- Prostatic Adenocarcinoma With Hormone Exposure Related Changes in a Patient With Hepatic Cirrhosis – Value of Autopsy in a Case Report (2016) (0)
- Abstract 3437: Cistromically-dominant class2 mutants of FOXA1 de-repress WNT signaling to drive prostate cancer metastasis (2020) (0)
- PD44-07 EFFECTIVENESS OF SERUM PSA, URINE PCA3 AND URINE TMPRSS2:ERG FUSION AS A NOVEL URINARY BIOMARKER PANEL IN CLINICAL PRACTICE (2015) (0)
- Abstract 4188: The role of microRNA-101 as a master tumor suppressor in cancer. (2013) (0)
- Abstract 1120: Identification and characterization of a novel androgen-regulated long non-coding RNA in prostate cancer. (2013) (0)
- 411: Defining Prostate Cancer Progression by Molecular Profiling of Laser Capture Micro Dissected Prostate Tissues (2006) (0)
- 1703: Noninvasive Detection of TMPRSS2:Erg Fusion Transcripts in the Urine of Men with Prostate Cancer (2007) (0)
- Metastasis SuppressorGeneRafKinase Inhibitor Protein ( RKIP ) Is aNovel Prognostic Marker in ProstateCancer (2005) (0)
- Supplementary Material for: Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells (2016) (0)
- Abstract 2055: Therapeutic resistance to BET bromodomain inhibition in prostate cancer (2017) (0)
- Abstract 3913: Fibroblast growth factor receptor 1 isoforms in prostate cancer bone metastases (2015) (0)
- MP56-10 RETROSPECTIVE ANALYSIS OF THE PERFORMANCE OF MIPS IN PATIENTS HAVING HAD MULTI-PARAMETRIC MRI (2020) (0)
- Gene-expression profiles in hereditary breast cancer. (2002) (0)
- Abstract 914: Development of a whole-urine, next-generation sequencing-based assay for early detection of aggressive prostate cancer (2019) (0)
- Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series (2020) (0)
- Abstract 2214: An integrative approach to reveal driver gene fusions from paired end sequencing data in cancer (2010) (0)
- [Developing a molecular marker profile for prognosis of the course of benign prostatic hyperplasia]. (2007) (0)
- Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04). (2023) (0)
- DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG (2020) (0)
- Genome-Wide Binding Studies of Acetyl-STAT3 Demonstrates a Novel Regulatory Pathway in Dendritic Cells (2015) (0)
- Abstract 5502: Androgen blockade confers sensitivity to PIKfyve inhibition in prostate cancer (2023) (0)
- Integrative whole exome, transcriptome, and clinical profiling of biliary tract cancers (BTCs). (2018) (0)
- Abstract 2836: Spatially resolved single-cell analysis of cellular plasticity and mechanisms of drug resistance (2018) (0)
- The authors reply [4] (2005) (0)
- DNA-Dependent Protein Kinase Promotes Metastatic Pathways in Triple-Negative Breast Cancer (2016) (0)
- Linc00402 Regulates Allogeneic T-Cell Function and T-Cell Receptor Signal Transduction (2021) (0)
- MP35-19 ASSOCIATION OF URINARY PCA3 AND TMPRSS2:ERG RISK GROUPS WITH DETECTION OF PROSTATE CANCER AT REPEAT BIOPSY IN MEN WITH AN INITIAL NEGATIVE PROSTATE BIOPSY (2018) (0)
- P-940 A novel methodology for the identification of lung cancertherapeutic targets via meta-analysis of gene expression microarrays (2005) (0)
- Serum PDGF Decreases during Combined Radiation and Androgen Deprivation Therapy for Prostate Cancer (2009) (0)
- Dynamic Recruitment of S ingle RNAs to Processing Bodies Depends on RNA Functionality Graphical (2019) (0)
- MP48-17 ANTERIOR PROSTATE CANCER: CLINICOPATHOLOGIC CHARACTERIZATION WITH BIOPSY CORRELATION (2015) (0)
- 186 Bioinformatics and gene discovery in prostate cancer (2009) (0)
- Abstract 2795: An onco-protein axis linking polycomb repressive complex 2 and polycomb repressive complex 1 through miRNAs in cancer (2011) (0)
- Abstract 3592: Targeting SWI/SNF ATPases in enhancer-addicted human cancers (2022) (0)
- PDCT-14. CLINICALLY INTEGRATED SEQUENCING SIGNIFICANTLY ALTERS THERAPY IN CHILDREN AND YOUNG ADULTS WITH HIGH-RISK GLIAL BRAIN TUMORS (2017) (0)
- 850: The Use of Autoantibody Signatures for the Prediction of Prostate Cancer Gleason Score (2006) (0)
- Abstract LB-246: Recurrent inactivating mutations in SPOP define a molecular subset of prostate cancer (2011) (0)
- CD8+ T cells regulate tumor ferroptosis by targeting the system xc− during cancer immunotherapy (2019) (0)
- 26th Pezcoller symposium: cancers driven by hormones. (2015) (0)
- Structural Characterization of KRAS with a Novel Interactor, Argonaute 2 (2018) (0)
- Abstract 3479: Identification and characterization of clinically relevant long non coding RNA PLUCAT1 in lung adenocarcinoma (2017) (0)
- Oncologists’ use of tumor sequencing findings and patient derived benefit. (2017) (0)
- Abstract 2578: An essential role forArgonaute 2inHRASandNRASdriven oncogenesis (2020) (0)
- Advancing Our Understanding of the Etiologies and Mutational Landscapes of Basal-Like, Luminal A, and Luminal B Breast Cancers (2014) (0)
- Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial (2016) (0)
- Abstract 2869: SChLAP1 mediated epigenetic modifications in prostate cancer (2015) (0)
- [11C]Sarcosine as PET tracer for prostate cancer imaging (2014) (0)
- Abstract PR16: Targeting cancer-specific kinase dependency for precision therapy (2013) (0)
- Use of comprehensive next-generation sequencing to identify pathogenic germline variants with therapeutic relevance in metastatic breast cancer. (2021) (0)
- Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer (2014) (0)
- A Search for Gene Fusions/Translocations in Breast Cancer (2013) (0)
- Abstract #1492: Role of microRNA-101 in regulating histone methyltransferase EZH2 in cancer (2009) (0)
- Abstract 3566: The long tail of significantly mutated genes in prostate cancer (2017) (0)
- Abstract 5679: Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment (2020) (0)
- SARS-CoV-2 Related Biomarker Investigation: Lessons from a Single Institution Autopsy Series (2021) (0)
- OUTLIER EXPRESSION OF SPINK1 IDENTIFIES AN AGGRESSIVE MOLECULAR SUBTYPE IN PROSTATE CANCERS WITHOUT ETS GENE FUSIONS (2008) (0)
- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination (2021) (0)
- Feature Selection and Molecular Classification of Cancer Using Genetic Programming 1 (2007) (0)
- Abstract P2-02-19: Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients (2016) (0)
- Abstract LB-058: Novel interactions of the RAS oncoprotein (2015) (0)
- Integrative Sequencing of Myeloproliferative Neoplasms (2019) (0)
- GAS6, KLK2, AND BMP7 DETECTED IN CIRCULATING TUMOR CELLS PREDICT RESISTANCE TO CHEMOTHERAPY IN MCRPC: PD71‐07 (2017) (0)
- Androgen receptor activation results in metabolite signatures of an aggressive prostate cancer phenotype: an NMR-based metabonomics study (2012) (0)
- Abstract IA021: Targeting epigenetic regulators of oncogenic transcription factors (2022) (0)
- Deciphering intratumor heterogeneity in clear cell renal cell carcinoma utilizing clinicopathologic and molecular platforms. (2022) (0)
- Prostate cancer expression profile (2002) (0)
- Exploring cell signaling pathways in breast cancer cells by gene expression profiling A molecular connection between HER2 and fatty acid synthase (2002) (0)
- Erratum: Triggers for genomic rearrangements: Insights into genomic, cellular and environmental influences (Nature Reviews Genetics 11 (819-829)) (2011) (0)
- UROLOGICAL ONCOLOGY: PROSTATE CANCER Autoantibody Signatures in Prostate Cancer (2006) (0)
- Abstract P6-12-05: Targeting estrogen receptor mutations for treatment of endocrine therapy resistance in breast cancer (2017) (0)
- TAMI-79. THERAPEUTIC REVERSAL OF PRENATAL PONTINE ID1 SIGNALING IN DIPG (2021) (0)
- 1438: Pharmacogenomic Analysis of Benign Prostatic Hyperplasia (2005) (0)
- Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer (2020) (0)
- MP68-20 EXPRESSION OF PDL1 (B7-H1) BEFORE AND AFTER NEOADJUVANT CHEMOTHERAPY IN UROTHELIAL CARCINOMA. (2015) (0)
- Empirical Bayes identification [correction of identication] of tumor progression genes from microarray data. (2007) (0)
- Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer (2015) (0)
- 608 COMBINING DNA-SEQ AND RNA-SEQ FOR DISCOVERY OF NOVEL MUTATIONS IN HUMAN PROSTATE CANCER (2011) (0)
- Development of selected reaction monitoring‐MS methodology to measure peptide biomarkers in prostate cancer (2011) (0)
- Abstract 1871: Alpha and beta isoforms of fibroblast growth factor receptor 1 in prostate cancer (2016) (0)
- PD19-11 INDIVIDUALIZED PROSTATE CANCER RISK ASSESSMENT BY SERUM PSA, URINE TMPRSS2:ERG AND URINE PCA3 (2014) (0)
- Abstract 2662: Interrogation of the landscape of long noncoding RNAs in breast cancer to identify an ER-regulated predictor of tamoxifen resistance (2016) (0)
- Abstract S4-05: Interrogating the landscape of long noncoding RNAs in breast cancer to identify predictors of tamoxifen resistance (2016) (0)
- Characterization of SPINK1 in Prostate Cancer (2011) (0)
- Abstract LB-132: The central role of EED in orchestration of polycomb group complexes (2014) (0)
- Keystone 1997: Return of the worm (1997) (0)
- Abstract 2162: Spatially resolved image-based transcriptomics using high-throughput single-molecule fluorescence in situ hybridization (HITSFISH) (2021) (0)
- Development and Validation of MyProstateScore 2.0 to Detect Clinically Significant Prostate Cancer (2023) (0)
- Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry (2018) (0)
- Abstract 712: Antitumor activity of SPINK1 monoclonal antibody in a subset ofSPINK1positiveETS-negative prostate cancer (2010) (0)
- Abstract 2803: The role of the sarcosine pathway in prostate cancer progression (2011) (0)
- Clinical Utility and Concordance of Upper Urinary Tract Cytology and Biopsy in Predicting Clinicopathologic Features of Upper Urinary Tract Urothelial Carcinoma (2019) (0)
- Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer? (2020) (0)
- Abstract P2-09-26: Frequency and mechanisms of elevated somatic mutation burden in metastatic breast cancer and response to immune checkpoint blockade (2018) (0)
- HGG-04. USE OF AN ADVANCED RNA-SEQ FUSION PIPELINE RESULTS IN THE TARGETED TREATMENT AND SUSTAINED CLINICAL RESPONSE OF CHILDREN WITH RECURRENT PEDIATRIC HIGH-GRADE GLIOMA (2019) (0)
- Molecular profiling of ETS and non‐ETS aberrations in prostate cancer patients from northern India (2021) (0)
- EXTH-47. THERAPEUTIC REVERSAL OF PRENATAL PONTINE ID1 SIGNALING IN DIPG (2019) (0)
- Abstract 2538: Role of Argonaute 2 in regulation of immune microenvironment in pancreatic cancer (2022) (0)
- Abstract 1763: A novel RNAin situhybridization approach highly sensitive for detection of Merkel cell polyomavirus (2017) (0)
- 410: Cleavage of E-Cadherin and the Role of an 80KDa Fragment in the Metastatic Progression of Prostate Cancer (2004) (0)
- ANALYSIS OF CDNA EXPRESSION PROFILES OF PROSTATE CARCINOMA APPLYING A NEURAL NETWORK (2006) (0)
- Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways (2019) (0)
- Abstract 5348: Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. (2013) (0)
- DEVELOPMENT OF A MULTIPLEX QUANTITATIVE PCR SIGNATURE TO PREDICT POOR OUTCOME IN BLADDER CANCER (2008) (0)
- Abstract 4497: Distinct structural classes of activating FOXA1 alterations in prostate cancer progression (2019) (0)
- Poster Session 54PROGNOSTIC BIOMARKERSMonday, 19 April, 14.00-15.30, Paris Room871 URINE MEASUREMENT OF TMPRSS2: ERG FOR THE EARLY DETECTION OF SIGNIFICANT PROSTATE CANCER (2010) (0)
- Abstract PR07: The landscape of molecular aberrations in pediatric and young adult cancer patients undergoing clinical sequencing for disease management: Novel biological findings from the Peds-MiOncoSeq study (2016) (0)
- Abstract 1945: Degradation of ERG transcription factor as a targeted therapy in B-cell and T-cell acute lymphoblastic leukemia (2018) (0)
- Indentification of a CTC-based gene expression signature predicting resistance to abiraterone and enzalutamide in mCRPC. (2017) (0)
- Abstract 4216: Novel RNAIn situhybridization method for the detection of ETV1, ETV4 and ETV5 rearrangements in prostate cancer. (2013) (0)
- Metabolomics of prostate cancer (2007) (0)
- Abstract 1398: Targeting novel co-activators of androgen receptor in castration resistant prostate cancer (2014) (0)
- 118 In vivo cellular reprogramming facilitates viral T antigen-driven Merkel cell carcinoma development in adult mice (2020) (0)
- Abstract 4078: EZH2 marks polyfunctional memory T cells and controls tumor immunity (2014) (0)
- 1407: Measuring Anti-Amacr Humoral Response as a Serum Assay to Distinguish Aggressive from Indolent Prostate Cancer (2005) (0)
- Abstract 975: Functional CRISPR screen towards identifying novel epigenetic co-factors of oncogenic AR-activity (2018) (0)
- Abstract 5099: Evaluating Ago2 as an oncogene in Kras-dependent lung carcinoma (2018) (0)
- Abstract 2678: A clonal expression biomarker improves prognostic accuracy: TRACERx lung (2019) (0)
- Abstract 3863: A subset of poorly prognostic pediatric posterior fossa ependymomas exhibit lowered H3K27me3 and DNA hypomethylation and show epigenetic similarities with H3K27M mutant diffuse intrinsic pontine gliomas (2017) (0)
- Detection of prognostic cancer-specific circular RNA in plasma. (2021) (0)
- DIPG-38. ID1 EXPRESSION CORRELATES WITH H3F3A K27M MUTATION AND EXTRA-PONTINE INVASION IN DIPG (2018) (0)
- Abstract LB-262: Estimation of tumor content from exome sequencing data (2011) (0)
- Tomlins Men with Elevated Serum PSA Fusion Transcript Stratifies Prostate Cancer Risk in TMPRSS 2 : ERG Urine (2011) (0)
- Erratum: Erratum: Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases (Science Translational Medicine (2015) 7 (287er3)) (2015) (0)
- Abstract PR10: HiClinc-1, a highly conserved Cancer-Testis lncRNA, regulates cell proliferation and tumor onset (2016) (0)
- Rational Approach to Implementation of PCA 3 into Clinical Care (2011) (0)
- Adolescent and parent perspectives on genomic sequencing to inform cancer care (2022) (0)
- CTC‐BASED GENE EXPRESSION FOR PREDICTING RESISTANCE TO ABIRATERONE AND ENZALUTAMIDE IN MCRPC: PD71‐06 (2017) (0)
- A method for forming a protein microarray system (2004) (0)
- Abstract 1001: Functional and mechanistic interrogation of androgen receptor degraders for the treatment of metastatic castration resistant prostate cancer (2019) (0)
- Characterization of the Pancreatic Adenocarcinoma Transcriptome by RNA Sequencing (2013) (0)
- Abstract IA14: Novel therapeutic targets in prostate cancer (2012) (0)
- Abstract C36: Transcriptome sequencing identifies PCAT-1, a novel lncRNA implicated in prostate cancer progression and therapeutic response to PARP inhibitors (2012) (0)
- Molecular and Cellular Pathobiology Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer (2012) (0)
- Abstract 3288: The landscape of circular RNA in cancer (2018) (0)
- Abstract B51: Ligand-independent EphA2 signaling through Akt is preferentially activated in prostate cancer bone metastases and is important for tumor growth (2012) (0)
- Abstract #5606: Analysis of genomic imbalances to detect gene fusions in cancer (2009) (0)
- Histone Methyltransferase Ezh2 Controls T-Cell Immunity by Regulating Bioenergetic Metabolism (2012) (0)
- Abstract 3347: Exploring the role of ASXL family of genes in enabling oncogenic AR-signaling in prostate cancer (2017) (0)
- Abstract 2780: Xenografts of human prostate cancer - a genetic profile analysis. (2013) (0)
- Development of a rational triple combination therapy for castrate-resistant prostate cancer (2016) (0)
- Abstracts from USCAP 2019: Autopsy (1-36) (2019) (0)
- Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in (2015) (0)
- Seminar article Cancer immunomics: Using autoantibody signatures in the early detection of prostate cancer (2006) (0)
- SUN-003 Targeting Androgen Receptor-CXCR7-MARK Signaling Axis in CRPC (2019) (0)
- Keystone 1997: return of the worm. Temarron, Colorado, February 18-23, 1997. (1997) (0)
- Tumor/normal genomic profiling in patients with metastatic solid tumors identifies pathogenic germline variants of therapeutic importance. (2020) (0)
- TAMI-29. MULTIFACTORIAL UPREGULATION OF ID1 DRIVES DIPG INVASIVENESS AND IS THERAPEUTICALLY TARGETABLE (2020) (0)
- Genetic diversity of NDUFV1-dependent mitochondrial complex I deficiency (2018) (0)
- Abstract LB-35: Reconstructing targetable pathways in lung cancer by integrating transcriptome, proteome and phosphoproteome (2012) (0)
- Abstract 677: TTK: A novel target for radiosensitization in triple-negative breast cancers (2018) (0)
- PD65-10 URINARY MYPROSTATESCORE (MPS) TO RULE OUT CLINICALLY-SIGNIFICANT CANCER IN MEN WITH EQUIVOCAL (PI-RADS 3) MULTIPARAMETRIC MRI: ADDRESSING AN UNMET CLINICAL NEED (2021) (0)
- Abstract 1700: Serial monitoring of single-cell circulating tumor cell genomics in metastatic lobular breast cancer to identify precision and immuno-oncology biomarkers with therapeutic implications (2022) (0)
- RKIP predicts PSA recurrence in prostate cancer (2004) (0)
- Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer (2021) (0)
- Abstract P4-02-04: Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance (2023) (0)
- Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (0)
- Humoral Response Profiling Using Protein Microarrays (2007) (0)
- PD53-01 DEVELOPMENT OF A WHOLE-URINE, MULTIPLEXED, NEXT GENERATION RNA-SEQUENCING ASSAY FOR AGGRESSIVE PROSTATE CANCER EARLY DETECTION (2020) (0)
- Rearrangements of genes MIPOL 1-ETV1. (2008) (0)
- The Identification and Characterization of Microtubule Associated Serine-Threonine Kinase Gene Fusions in Breast Cancer (2013) (0)
- Competing for enhancers: PVT1 fine-tunes MYC expression (2018) (0)
- Integrative genomic profiling of RCC treated with second-line nivolumab. (2020) (0)
- Abstract A21: Loss of Argonaute 2 leads to oncogene-induced senescence in mutant RAS-driven cancer (2020) (0)
- MP17-11 REFINEMENT AND EXTERNAL VALIDATION OF A NOVEL MULTIPLEX URINE TEST FOR HIGH-GRADE PROSTATE CANCER (2023) (0)
- Abstract IA18: The application of integrative sequencing for precision oncology (2015) (0)
- Abstract 3929: The role of chromosome architecture in the generation of gene fusions in prostate cancer (2010) (0)
- -Splicing cis Chimera in Prostate Cancer: Spotlight on SLC45A3-ELK4 (2012) (0)
- Gene-Expression Profiles in Hereditary Breast Cancer: On: Gene-expression profiles in hereditary breast cancer. Hedenfalk I, Duggan, D, Chen Y, et al. N Engl J Med 2001;344:539–48 (2002) (0)
- Metabolite biomarkers of prostate cancer (2008) (0)
- Abstract 3636: Targeting the MLL complex in castration resistant prostate cancer (2015) (0)
- A novel methodology for the identification of drugable enzymes as targets in cancer via meta analysis of gene expression microarrays (2005) (0)
- Identifying significant associations using free text problem summary lists in a clinical data repository. (2007) (0)
- Speed reading the epigenome and genome. (2023) (0)
- MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions (2018) (0)
- Abstract 3573: Identification and functional characterization of prognostic long non coding RNA LADDER in lung cancer (2019) (0)
- Multiplex panel of metabolomic markers for early detection of prostate cancer. (2011) (0)
- The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc 1 , 2 (2017) (0)
- Abstract 1685: Overcoming acquired resistance to PROTAC degraders (2023) (0)
- Abstracts from USCAP 2019: Autopsy (1-36) (2019) (0)
- Using Departments of Pathology And (2011) (0)
- Abstract A17: Inhibiting polo-like kinases for the treatment of pancreatic cancer: Targeting kinase outliers for personalized therapy. (2012) (0)
- Abstract 2926: Nomination and characterization of TTK for radiosensitization in basal-like breast cancers (2019) (0)
- Translating Science to Medicine: When Will the Rubber Meet the Road? (2019) (0)
- Abstract A20: An essential role for Argonaute 2 in mouse models of KRAS driven cancers (2020) (0)
- next-generation RNA sequencing Discovery of non-ETS gene fusions in human prostate cancer using Material Supplemental (2010) (0)
- Abstract 957: An essential role forArgonaute 2in mouse models ofKRAS-driven cancers (2019) (0)
- Abstract 730: Genomic characterization of hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare and aggressive kidney cancer (2019) (0)
- Abstract C8: Targeting the DNA-damage repair and transcriptional regulatory functions of PARP1 therapeutically in prostate cancer (2012) (0)
- PD64-08 IDENTIFICATION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A NOVEL MULTIPLEXED URINE BIOMARKER PANEL (2019) (0)
- Abstract LB-008: KRAS engages AGO2 to enhance cellular transformation (2016) (0)
- Abstract IA02: Defects in DNA repair genes revealed by clinical sequencing of advanced cancer patients (2017) (0)
- Abstract 3207: Application of an antibody-free, highly sensitive PRISM-SRM proteomics approach for monitoring low abundance proteins and protein isoforms in cell lines and tumor tissue. (2013) (0)
- Antitumour Activity of the Poly(Adp-Ribose) Polymerase (Parp) Inhibitor Olaparib in Unselected Sporadic Castration Resistant Prostate Cancer (Crpc) in the Toparp Trial (2015) (0)
This paper list is powered by the following services:
Other Resources About Arul Chinnaiyan
What Schools Are Affiliated With Arul Chinnaiyan?
Arul Chinnaiyan is affiliated with the following schools:
